Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Baxter Healthcare presents phase I inhaled insulin study results

Baxter Healthcare Corporation announced results of a Phase I study that evaluated pulmonary insulin produced with Baxter's PROMAXX microsphere technology and administered using a small, standard dry powder inhaler.

24 Apr 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

Cytokinetics initiates of phase II clinical trial for CK-1827452

Cytokinetics has announced the initiation of a Phase II clinical trials program evaluating CK-1827452, a novel cardiac myosin activator for the potential treatment of patients with either acutely decompensated or chronic heart failure.

15 Apr 2007

Pharmacopeia announces positive results in hypertension and diabetic nephropathy trial

Pharmacopeia ( NASDAQ:PCOP ) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.

11 Apr 2007

Bayer Healthcare Pharmaceuticals launches in the U.S.

Bayer HealthCare Pharmaceuticals Inc. today announced its official U.S. launch. The new company incorporates the former Berlex Inc.into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

5 Apr 2007

Study results on bifeprunox in patients with schizophrenia

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week.

2 Apr 2007

PPD licenses dyslipidemia statin from Ranbaxy

Ranbaxy Laboratories and PPD, Inc. have announced that PPD has acquired an exclusive worldwide license to develop, manufacture and market Ranbaxy's novel statin for the treatment of dyslipidemia.

27 Feb 2007

Natural gum improves gold nanoparticles for cancer imaging

Gold nanoparticles have shown significant promise as agents to detect and treat cancer, but researchers have had difficulty creating gold nanoparticles that have suitable pharmacological properties for use in humans.

12 Feb 2007

Neuren reports successful NNZ-2566 safety trial results

Neuren Pharmaceuticals Ltd has successfully completed a Phase 1 safety and tolerability trial of its second lead candidate, NNZ-2566, which is being developed to treat traumatic brain injury (TBI).

16 Jan 2007

In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles

In an attempt to determine what factors make one nanoparticle better than another at targeting tumors, a team of investigators in Korea have conducted a systematic tumor-targeting study of a variety of self-assembling nanoparticles.

18 Dec 2006

Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence

In the first experiments of their kind, researchers have determined that carbon nanotubes injected directly into the bloodstream of research lab animals cause no immediate adverse health effects and circulate for more than one hour before they are removed by the liver.

18 Dec 2006

Polymer coating improves tumor-targeting nanoparticles

Adding a thin coating of the biocompatible polymer poly(ethylene glycol) (PEG) to the surface of sulfur-modified, or thiolated, nanoparticles designed to fall apart inside tumors, prolongs the time that the resulting nanoparticles remain in tumors.

13 Nov 2006

A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas

In a dramatic demonstration of the power of nanotechnology, a team of investigators has designed a nanoscale, polymeric drug delivery vehicle that when loaded with a widely used anticancer agent cures colon cancer in mice with a single dose.

13 Nov 2006

Cancer Research Technology to present discovery updates at BioEurope 2006

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that Phil L'Huillier, the Director of Business Management, will present at the BioEurope 2006 Annual International Partnering Conference.

6 Nov 2006

Photochemistry creates drug-trapping nanoparticles

Many of the most potent anticancer agents are poorly soluble in water, presenting a challenge for medicinal chemists who must develop methods of delivering these drugs in the watery environment of the human body.

9 Oct 2006

Licensing arrangement reached for antiepileptic drug developed at Hebrew University

A worldwide licensing arrangement for development, production and marketing of an antiepileptic drug created at the Hebrew University of Jerusalem has been signed by Shire Pharmaceuticals with Yissum, the Hebrew University's technology transfer company.

5 Sep 2006

Emergent BioSolutions awarded $3.8 million to develop anthrax immune globulin therapeutic

Emergent BioSolutions has announced that it has been awarded two grants from the National Institute of Allergy and Infectious Diseases (NIAID) totaling $3.8 million to support the development of the company's anthrax immune globulin (AIG) therapeutic product.

1 Sep 2006

Morphotek granted two European technology patents

Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetically Altered Antigens."

30 Aug 2006